Recombinant Tafazzin (TAZ)

CMD3A; EFE2; EFE; BTHS; XAP-2; G4.5; Barth syndrome; Endocardial Fibroelastosis 2; Cardiomyopathy,Dilated 3A(X-Linked)

  • Recombinant Tafazzin (TAZ) Packages (Simulation)
  • Recombinant Tafazzin (TAZ) Packages (Simulation)
  • RPE564Ra01.jpg Figure. SDS-PAGE
  • Certificate ISO9001: 2008, ISO13485: 2003 Registered

SEQUENCE of the Recombinant Tafazzin (TAZ)

USAGE of the Recombinant Tafazzin (TAZ)

Reconstitute in 20mM Tris, 150mM NaCl (pH8.0) to a concentration of 0.1-1.0 mg/mL. Do not vortex.

STORAGE of the Recombinant Tafazzin (TAZ)

Avoid repeated freeze/thaw cycles. Store at 2-8°C for one month. Aliquot and store at -80°C for 12 months.

STABILITY of the Recombinant Tafazzin (TAZ)

The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37°C for 48h, and no obvious degradation and precipitation were observed. The loss rate is less than 5% within the expiration date under appropriate storage condition.

Related products

Catalog No. Organism species: Rattus norvegicus (Rat) Applications (RESEARCH USE ONLY!)
RPE564Ra01 Recombinant Tafazzin (TAZ) Positive Control; Immunogen; SDS-PAGE; WB.
PAE564Ra01 Polyclonal Antibody to Tafazzin (TAZ) WB; IHC; ICC; IP.
GUESTBOOK